{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:30:31Z","timestamp":1793043031032,"version":"4.5.0"},"reference-count":118,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Although immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) have transformed the treatment of non\u2013small cell lung cancer (NSCLC) across disease stages, real-world access remains highly unequal worldwide. Persistent cost barriers, fragmented reimbursement frameworks, and heterogeneous regulatory pathways limit equitable availability. The rapid proliferation of me-too agents has been proposed to counter monopolies; yet, this expansion has not consistently improved affordability. Heterogeneous evidentiary requirements\u2014along with differences in clinical end points, comparator selection, crossover policies, and treatment duration\u2014fragment therapeutic markets and complicate assessment of incremental clinical benefit. Divergent regulatory decisions, particularly between the US Food and Drug Administration and European Medicines Agency, underscore how trial design and geographic representation influence drug availability, especially when approvals rely on single-country data sets. These challenges are amplified in perioperative treatment strategies and rare oncogene-defined subgroups, where feasibility constraints and limited clinical equipoise hinder large randomized trials. As a result, an increasingly crowded therapeutic landscape makes cross-trial comparisons difficult and allows disparities in patient access to persist despite multiple approved therapies. Dose selection has historically followed maximum tolerated dose principles, even when preclinical and pharmacologic data suggest activity plateaus at lower exposure of ICI and TT. Dose and schedule optimization\u2014through reduced dosing, extended intervals, or other deintensified strategies\u2014therefore represents a rational and ethically grounded approach with a meaningful clinical impact. Such strategies may preserve efficacy while improving tolerability, reducing treatment burden, and mitigating financial toxicity, particularly in resource-limited settings. Aligning regulatory frameworks with dose optimization could promote more scalable, equitable, and sustainable NSCLC innovation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-517100","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:59:06Z","timestamp":1775678346000},"source":"Crossref","is-referenced-by-count":1,"title":["Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026"],"prefix":"10.1200","volume":"46","author":[{"given":"Martina","family":"Bortolot","sequence":"first","affiliation":[{"name":"Department of Pulmonary Diseases, Maastricht University Medical Centre (+), GROW Research Institute for Oncology and Reproduction, Maastricht, the Netherlands"},{"name":"Department of Medical Oncology, CRO IRCSS Aviano, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.L.","family":"Saw","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Pietroluongo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology, Thoracic Oncology Program, The University of Chicago Medicine, Chicago, IL"},{"name":"Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Rajath","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Malignant Disease Treatment Center, Army Hospital Research and Referral, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Malignant Disease Treatment Center, Army Hospital Research and Referral, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Garassino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology, Thoracic Oncology Program, The University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":true,"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France"},{"name":"Paris-Saclay University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","volume-title":"Cancer Statistics","year":"2026","unstructured":"Cancer Statistics: SEER, 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html?utm"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400443"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1760"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102995"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00196-0"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103261"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01254-x"},{"key":"e_1_3_2_10_2","volume-title":"Global Oncology Trends 2023","year":"2023","unstructured":"Global Oncology Trends 2023. IQVIA, 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2023"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01324"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00269-8"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.128"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432524"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2021.03.001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.021"},{"key":"e_1_3_2_22_2","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cejemly-epar-product-information_en.pdf"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00630-6"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.06.002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02267-y"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70024"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432516"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01970-w"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01538-w"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.053"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101191"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae205"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00515"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00275"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2314327"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511065"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.088"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3617"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0703"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2187"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.135"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2644"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2109826"},{"key":"e_1_3_2_54_2","first-page":"29","article-title":"A review of the pharmacokinetic characteristics of immune checkpoint inhibitors and their clinical impact factors","volume":"16","author":"Liu J-C","year":"2023","unstructured":"Liu J-C, Yu H-J: A review of the pharmacokinetic characteristics of immune checkpoint inhibitors and their clinical impact factors. Pharmgenomics Pers Med 16:29-36, 2023","journal-title":"Pharmgenomics Pers Med"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2842"},{"key":"e_1_3_2_57_2","volume-title":"Global Oncology Trends 2025","year":"2025","unstructured":"Global Oncology Trends 2025. IQVIA, 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2025"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02347"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw174"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115564"},{"key":"e_1_3_2_62_2","article-title":"Effectiveness of immune checkpoint inhibitors in various tumor types treated by low, per-weight, and conventional doses at a tertiary care center in Mumbai","author":"Patel A","unstructured":"Patel A, Hande V, Mr K, et al: Effectiveness of immune checkpoint inhibitors in various tumor types treated by low, per-weight, and conventional doses at a tertiary care center in Mumbai. JCO Glob Oncol 10.1200\/GO.23.00312","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01546"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1315"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000332"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011622"},{"key":"e_1_3_2_68_2","article-title":"Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: A systematic review","author":"Hoyek C","unstructured":"Hoyek C, Zheng-Lin B, Bauernfeind JJ, et al: Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: A systematic review. JCO Glob Oncol 10.1200\/GO-24-00409","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_69_2","article-title":"Low-dose Anti-PD(L)1 for the treatment of solid malignancies","author":"Souza IAdA","unstructured":"Souza IAdA, Dobbert BdM, Sao Jose BG, et al: Low-dose Anti-PD(L)1 for the treatment of solid malignancies. JCO Glob Oncol 10.1200\/GO.24.00122","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1788649"},{"key":"e_1_3_2_71_2","article-title":"Performance of low-dose immunotherapy and standard-dose immunotherapy in microsatellite instability-high metastatic colorectal cancer: Real-world data (CLouD-High study)","author":"Trikha M","unstructured":"Trikha M, Sarkar L, Dhanawat A, et al: Performance of low-dose immunotherapy and standard-dose immunotherapy in microsatellite instability-high metastatic colorectal cancer: Real-world data (CLouD-High study). JCO Glob Oncol 10.1200\/GO.24.00141","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19197-y"},{"key":"e_1_3_2_73_2","volume-title":"A Randomised open-label Phase III Trial of Reduced Frequency Pembrolizumab Immunotherapy for first-line Treatment of Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel multi-arm frequency-response Optimisation Design","author":"Imperial College London","year":"2024","unstructured":"Imperial College London: A Randomised open-label Phase III Trial of Reduced Frequency Pembrolizumab Immunotherapy for first-line Treatment of Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel multi-arm frequency-response Optimisation Design. 2024. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05085028"},{"key":"e_1_3_2_74_2","volume-title":"Maintenance Pembrolizumab at Usual or Low Dose in Non-squamous Lung Cancer: A Non-inferiority Study","author":"Gustave Roussy, Cancer Campus, Grand Paris","year":"2025","unstructured":"Gustave Roussy, Cancer Campus, Grand Paris: Maintenance Pembrolizumab at Usual or Low Dose in Non-squamous Lung Cancer: A Non-inferiority Study, 2025. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05692999"},{"key":"e_1_3_2_75_2","volume-title":"A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (\u00b1 Pemetrexed) Until Progression Versus Observation (\u00b1 Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy plus Pembrolizumab Induction Treatment in Patients with Stage IV Non-small Cell Lung Cancer (NSCLC)","author":"Interg","year":"2025","unstructured":"Interg.roupe Francophone de Cancerologie Thoracique: A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (\u00b1 Pemetrexed) Until Progression Versus Observation (\u00b1 Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy plus Pembrolizumab Induction Treatment in Patients with Stage IV Non-small Cell Lung Cancer (NSCLC), 2025. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05255302"},{"key":"e_1_3_2_76_2","volume-title":"A Phase III RCT Comparing Low Dose Immunotherapy (Nivolumab) Combined with Standard Chemotherapy vs Standard Chemotherapy as first-line Treatment in Patients with Locally Advanced or Metastatic NSCLC","author":"Alaga DAA","year":"2025","unstructured":"Alaga DAA: A Phase III RCT Comparing Low Dose Immunotherapy (Nivolumab) Combined with Standard Chemotherapy vs Standard Chemotherapy as first-line Treatment in Patients with Locally Advanced or Metastatic NSCLC, 2025. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT07050043"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.640"},{"key":"e_1_3_2_78_2","volume-title":"A Biomarker Study of Low-Dose IL-2 plus Pembrolizumab in Patients with Stage IV Non-small Cell Lung Cancer (NSCLC)","author":"Carlisle J","year":"2025","unstructured":"Carlisle J: A Biomarker Study of Low-Dose IL-2 plus Pembrolizumab in Patients with Stage IV Non-small Cell Lung Cancer (NSCLC), 2025. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05493566"},{"key":"e_1_3_2_79_2","article-title":"Real-world outcomes of induction chemotherapy with or without low-dose nivolumab for stage III non-small cell lung cancer ineligible for Up-Front local therapy: A propensity score-matched analysis","author":"Marimuthu PK","unstructured":"Marimuthu PK, Georgy JT, Philip DSJ, et al: Real-world outcomes of induction chemotherapy with or without low-dose nivolumab for stage III non-small cell lung cancer ineligible for Up-Front local therapy: A propensity score-matched analysis. JCO Glob Oncol 10.1200\/GO-24-00256","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.12.015","article-title":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant therapy for localized triple negative breast cancer (TNBC). [PLANeT trial\u2014Pembrolizumab low dose in addition to NACT in TNBC]","author":"Arora A","year":"2025","unstructured":"Arora A, Bhaskarane H, Tansir G, et al: A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant therapy for localized triple negative breast cancer (TNBC). [PLANeT trial\u2014Pembrolizumab low dose in addition to NACT in TNBC]. Ann Oncol, 2025","journal-title":"Ann Oncol"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.712"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00643-6"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh182"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13714"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114204"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw322"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0190-1"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.028"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.128"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03355-2"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16199"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13223"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091844"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00708"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00457"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.113"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.026"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101955"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S494112"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01432-4"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-243"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1721"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70362-6"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.11.025"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.018"},{"issue":"4143","key":"e_1_3_2_111_2","article-title":"Clinical relevance of starting alectinib at a reduced dose in patients with ALK-positive non-small cell lung cancer","volume":"10","author":"Kim J","unstructured":"Kim J, Kim M-J, Kim J, et al: Clinical relevance of starting alectinib at a reduced dose in patients with ALK-positive non-small cell lung cancer. Cancer Res Treat 10.4143\/crt.2024.1209 [epub ahead of print on April 24, 2025]","journal-title":"Cancer Res Treat"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.11.004"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00581"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107954"},{"key":"e_1_3_2_115_2","article-title":"Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14\u2013skipping+ NSCLC","volume":"43","author":"Mohamed SR","year":"2025","unstructured":"Mohamed SR, Berg J, Widick P, et al: Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14\u2013skipping+ NSCLC. J Clin Oncol 43, 2025 (suppl 16; abstr e20671)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_116_2","volume-title":"Commissioner O of The: Project Optimus","year":"2024","unstructured":"FDA: Commissioner O of The: Project Optimus. 2024. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12196"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00349"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.003"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-517100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:59:10Z","timestamp":1775678350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-517100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-517100"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-517100","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e517100"}}